Physician profile
Kaling Cheung
NPI 1881643831
$14,678.90
in general payments reported to CMS, 2019-2025
40 companies · $3,061 in 2025
The $3,061 reported for 2025 was more than what 83% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $474 · 2020: $295 · 2021: $1,780 · 2022: $3,036 · 2023: $3,012 · 2024: $3,021 · 2025: $3,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,346 · Education: $747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,345.98 |
| Education | $747.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,152.08 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,906.78 | 2019-2025 | Ofev, Jascayd |
| Astrazeneca Pharmaceuticals LP | $1,863.38 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Jazz Pharmaceuticals INC. | $866.92 | 2020-2025 | Xywav |
| Harmony Biosciences LLC | $803.81 | 2021-2025 | Wakix |
| Inspire Medical Systems, INC. | $643.33 | 2023-2025 | Inspire |
| Genzyme Corporation | $626.30 | 2021-2025 | |
| Baxter Healthcare | $591.63 | 2022-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Merck Sharp & Dohme LLC | $469.80 | 2020-2025 | Zerbaxa, Belsomra, Recarbrio |
| Amgen INC. | $360.64 | 2021-2025 | Tezspire |
| Vanda Pharmaceuticals INC. | $341.29 | 2023-2024 | Hetlioz |
| Grifols USA, LLC | $321.63 | 2023-2025 | Prolastin-C Liquid |
| Insmed, INC. | $283.87 | 2023-2025 | Arikayce, Brinsupri |
| Actelion Pharmaceuticals US, INC. | $275.49 | 2022-2023 | Uptravi, Opsumit |
| United Therapeutics Corporation | $268.84 | 2022-2025 | Tyvaso, Tyvaso |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $258.97 | 2023-2025 | |
| Philips North America LLC | $254.26 | 2021-2025 | Vest Therapy Und, Full Face Masks - Over The Head, (Di5) Full Face Masks - Over The Head |
| Fisher & Paykel Healthcare INC | $223.78 | 2022-2025 | Fisher & Paykel Healthcare |
| Avadel Cns Pharmaceuticals, LLC | $191.58 | 2024-2025 | Lumryz |
| Resmed Corp | $187.54 | 2019-2025 | |
| Advanced Respiratory, INC | $174.52 | 2020-2021 | |
| Electromed, INC. | $171.20 | 2022-2025 | Smartvest |
| Comsort, INC | $150.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $148.20 | 2019-2023 | Xarelto |
| Pulmonx Corporation | $134.61 | 2021-2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Takeda Pharmaceuticals U.S.A., INC. | $133.53 | 2021-2024 | Glassia, Hyqvia |
| Genentech USA, INC. | $130.51 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $126.02 | 2019-2023 | |
| Lilly USA, LLC | $101.89 | 2025 | Zepbound, Mounjaro |
| Teva Pharmaceuticals USA, INC. | $86.36 | 2019-2022 | |
| Axsome Therapeutics, INC. | $83.32 | 2023-2024 | Sunosi |
| Abbvie INC. | $68.43 | 2022 | |
| La Jolla Pharmaceutical Company | $47.29 | 2023-2024 | Giapreza |
| Sunovion Pharmaceuticals INC. | $43.19 | 2019 | |
| Vifor Pharma, INC. | $39.06 | 2024-2025 | Zemaira, Veltassa |
| Eisai INC. | $36.88 | 2021 | |
| Verona Pharma, INC. | $32.63 | 2025 | Ohtuvayre |
| Itamar Medical INC | $31.19 | 2023-2025 | Watchpatone |
| Pfizer INC. | $26.06 | 2021 | |
| Mayne Pharma Commercial LLC | $22.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaling Cheung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.